Cargando…
MDM2 Antagonists Counteract Drug-Induced DNA Damage
Antagonists of MDM2-p53 interaction are emerging anti-cancer drugs utilized in clinical trials for malignancies that rarely mutate p53, including melanoma. We discovered that MDM2-p53 antagonists protect DNA from drug-induced damage in melanoma cells and patient-derived xenografts. Among the tested...
Autores principales: | Vilgelm, Anna E., Cobb, Priscilla, Malikayil, Kiran, Flaherty, David, Andrew Johnson, C., Raman, Dayanidhi, Saleh, Nabil, Higgins, Brian, Vara, Brandon A., Johnston, Jeffrey N., Johnson, Douglas B., Kelley, Mark C., Chen, Sheau-Chiann, Ayers, Gregory D., Richmond, Ann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652019/ https://www.ncbi.nlm.nih.gov/pubmed/29030058 http://dx.doi.org/10.1016/j.ebiom.2017.09.016 |
Ejemplares similares
-
Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma
por: Yan, Chi, et al.
Publicado: (2023) -
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade
por: Yan, Chi, et al.
Publicado: (2021) -
The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo
por: Lavender, Nicole, et al.
Publicado: (2017) -
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
por: Yan, Chi, et al.
Publicado: (2021) -
Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients
por: Yan, Chi, et al.
Publicado: (2022)